Why the study?
Does pioglitazone increase heart failure morbidity and mortality in patients with type 2 diabetes and preexisting cardiovascular disease?
Population
5,238 patients with type 2 diabetes and preexisting cardiovascular disease. Excluded: New York Heart…
Comparison
Pioglitazone vs Placebo
Design
RCT, Randomized to pioglitazone or placebo
Authors
Loading...
Clinicians should monitor for HF with pioglitazone in T2D with CVD; extends evidence that incident HF need not raise mortality.
Does pioglitazone increase heart failure morbidity and mortality in patients with type 2 diabetes and preexisting cardiovascular disease?
Although pioglitazone increases the risk of serious heart failure events in patients with type 2 diabetes and macrovascular disease, it does not increase subsequent mortality or morbidity among those who develop heart failure.
Erdmann et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: